Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Talampanel for Amyotrophic Lateral Sclerosis (ALS) (ALS)

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries Identifier:
First received: June 10, 2008
Last updated: October 20, 2011
Last verified: October 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2010
  Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 16, 2011